Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis

Patent metadata

Field	Value
Publication number	US-10806803-B2
Application number	US-201515326985-A
Country	US
Kind code	B2
Filing date	Jul 17, 2015
Priority date	Jul 17, 2014
Publication date	Oct 20, 2020
Grant date	Oct 20, 2020

Abstract

Provided are compounds and compositions for targeting macrophages and other CD206 high expressing cells.

First claim

What is claimed is:

1. A compound of Formula (II):

wherein
each X is independently H, L 1 -A, or L 2 -R;
each L 1 and L 2 are independently linkers;
each A independently comprises one selected from the group consisting of a therapeutic agent, a detection label, and H;
each R independently comprises one selected from the group consisting of a CD206 targeting moiety and H;
and
n is an integer greater than zero; and
wherein at least one X is L 1 -A wherein L 1 comprises a hydrazone and at least one X is L 2 -R wherein at least one L 2 comprises —(CH 2 )pS(CH 2 )qNH—, wherein p and q independently are integers from 0 to 5.

2. A compound according to claim 1 , wherein at least one R is selected from mannose, fucose, and n-acetylglucosamine.

3. A compound according to claim 1 , wherein at least one A is selected from a chemotherapeutic agent; an antibiotic; an immunological adjuvant; a compounds useful for treating tuberculosis; a steroid; a nucleotide; a peptide; a protein; microRNA; siRNA; an antiviral; an antigens; or a metal.

4. A compound according to claim 1 , wherein at least one A is a compound useful for treating tuberculosis.

5. A compound according to claim 1 , wherein at least one A is doxorubicin, isoniazid, gadolinium, gallium, silver, or a silver antibiotic.

6. A compound according to claim 1 wherein at least one L 1 is a C 2-12 hydrocarbon chain optionally interrupted by up to three heteroatoms selected from the group consisting of O, S and N.

7. A compound according to claim 1 wherein at least one L 1 comprises (CH 2 ) p S(CH 2 ) q NH, wherein p and q are integers from 0 to 5.

8. A compound according to claim 1 wherein at least one L 2 is a C 2-12 hydrocarbon chain optionally interrupted by up to three heteroatoms selected from the group consisting of O, S and N.

9. A compound according to claim 1 , wherein at least one L 1 -A comprises a chelator.

10. A compound of Formula (4):

wherein
R is mannose,
n is an integer greater than zero, and

11. A compound of Formula (7):

wherein
R is mannose,
R′ is H or CH 3 ,
n is an integer greater than zero, and

Assignees

• Ohio State Innovation Foundation
• Cardinal Health 414 Llc
• Cope Frederick O

Inventors

• Schlesinger Larry
• Bachelder Eric
• Cope Frederick O

Classifications

• A61K49/0054

  Macromolecular compounds, i.e. oligomers, polymers, dendrimers · CPC title

• C08B37/0021

  Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran · CPC title

• A61K47/61

  the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title

• A61K31/4409

  only substituted in position 4, e.g. isoniazid, iproniazid · CPC title

• A61K31/704

  attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title